22.79

2.06% 0.46

After Hours: 22.90 0.11 +0.48%

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $22.79, with a volume of 3.19M. It is up +2.06% in the last 24 hours and down -6.21% over the past month. Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Previous Close:

$22.33

Open:

$22.42

24h Volume:

3.19M

Relative Volume:

2.62

Market Cap:

$2.78B

Revenue:

$588.99M

Net Income/Loss:

$214.33M

P/E Ratio:

13.53

EPS:

1.6844

Net Cash Flow:

$208.61M

1W Performance:

-1.89%

1M Performance:

-6.21%

6M Performance:

+15.22%

1Y Performance:

-1.60%

1-Day Range:

$22.16

$22.86

1-Week Range:

$22.16

$23.57

52-Week Range:

$19.05

$26.58

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1110)

Industry

Biotechnology (621)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

182

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ALNY, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	22.79	2.78B	588.99M	214.33M	208.61M	1.6844
VRTX Vertex Pharmaceuticals Inc	454.00	115.33B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	732.87	77.48B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	312.17	41.40B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	663.93	41.09B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	275.28	30.56B	5.36B	287.73M	924.18M	2.5229

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Mar 21, 2026

Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Mar 21, 2026

Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN

Mar 21, 2026

Mar 20, 2026

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 20, 2026

CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 20, 2026

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Australia

Mar 20, 2026

Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn

Mar 20, 2026

Mar 19, 2026

Market Wrap: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Weekly Recap & Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 19, 2026

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 19, 2026

Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan

Mar 19, 2026

Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart

Mar 19, 2026

Mar 18, 2026

Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks

Mar 18, 2026

Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com

Mar 18, 2026

Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mar 18, 2026

Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan

Mar 18, 2026

Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN

Mar 18, 2026